Bayforest Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Bayforest Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-392	Closed	-$303K	–	1055
2025 Q4	$303K	Buy	+392	New	+$266K	0.23%	128

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Bayforest Capital's REGN Position: Q1 2026 in Review

Bayforest Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 392 shares — an estimated $303K sold.

Bayforest Capital first reported a position in REGN in Q4 2025 and held it in 1 quarter. The position peaked at $303K in Q4 2025. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Bayforest Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bayforest Capital sold 392 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $303K.
Bayforest Capital first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Bayforest Capital's Regeneron Pharmaceuticals position peaked at $303K in Q4 2025.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Bayforest Capital's 13F filing for Q1 2026, filed 15 Apr 2026.